<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110838">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765465</url>
  </required_header>
  <id_info>
    <org_study_id>S-2012-E0816-00001</org_study_id>
    <nct_id>NCT01765465</nct_id>
  </id_info>
  <brief_title>Effect of Rowachol on Prevention of Postcholecystectomy Syndrome</brief_title>
  <official_title>Effect of Rowachol on Prevention of Postcholecystectomy Syndrome After Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmbio Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DongGuk University</source>
  <oversight_info>
    <authority>Korea: Ministry for Health, Welfare and Family Affairs</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postcholecystectomy syndrome (PCS) includes a heterogeneous group of diseases, usually
      manifested by the presence of abdominal symptoms following gallbladder removal. The
      pathogenesis of PCS has not been identified; therefore there is no consensus of medical
      treatment on PCS. The Action of Rowachol are to inhibit hepatic 3-hydroxy-3-methylglutaric
      acid(HMG)-coenzyme A(CoA) reductase, to inhibits cholesterol nucleation in bile from
      patients with cholesterol gallstones, and to promote biliary lipid secretion.

      The purpose of this study is to determine whether Rowachol is useful in the prevention of
      PCS and symptoms change after laparoscopic cholecystectomy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Right upper quadrant(RUQ) pain score</measure>
    <time_frame>baseline and postoperative 3 months after</time_frame>
    <safety_issue>No</safety_issue>
    <description>Right upper quadrant(RUQ) pain by European Organization for Research and Treatment of Cancer(EORTC) quality of life questionnaire(QLQ) C-30 No. 9, 19 at baseline and postoperative 3 months after.
The difference of Pain score from 3months to baseline will be calculated by EORTC QLQ C-30 manual.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changing pattern of liver function test</measure>
    <time_frame>baseline and postoperative 3 months after</time_frame>
    <safety_issue>No</safety_issue>
    <description>3 months minus baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Postcholecystectomy Syndrome</condition>
  <arm_group>
    <arm_group_label>Rowachol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rowachol</intervention_name>
    <arm_group_label>Rowachol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathologic diseases scheduled for laparoscopic cholecystectomy

        Exclusion Criteria:

          -  Current immunosuppressive therapy

          -  Chemotherapy within 4 weeks before operation

          -  Radiotherapy completed longer than 4 weeks before operation

          -  Inability to follow the instructions given by the investigator

          -  Severe psychiatric or neurologic diseases

          -  Drug- and/or alcohol-abuse according to local standards

          -  Participation in another intervention-trial with interference of a primary  or
             secondary endpoint of this study

          -  Lack of compliance

          -  Lack of informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Woong Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DongGuk University College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>In Woong Han, M.D.</last_name>
    <phone>82-31-961-7567</phone>
    <email>cardioman76@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>DongGuk University Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In Woong Han, M.D.</last_name>
      <phone>82-31-961-7567</phone>
      <email>cardioman76@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Min Gu Oh, M.D., PhD.</last_name>
      <phone>82-31-961-7261</phone>
      <email>mgo59@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>In Woong Han, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Gu Oh, M.D., PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Eun Lee, M.D., PhD.</last_name>
      <phone>82-10-8912-3073</phone>
      <email>selee@cau.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seung Eun Lee, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>DongGuk University</investigator_affiliation>
    <investigator_full_name>In Woong Han</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>postcholecystectomy syndrome</keyword>
  <keyword>laparoscopic cholecystectomy</keyword>
  <keyword>Rowachol</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Postcholecystectomy Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
